Randomisation
The two arms of the study were: (1) intervention arm: immediate access to the intervention with symptom monitoring for 4 weeks; and (2) comparator arm: delayed intervention i.e., usual care for 4 weeks (defined as receiving any treatments they would otherwise access) followed by access to the intervention/symptom monitoring for 4 weeks. Participants were randomised using a remote, secure web-based clinical research system (P1vital® ePRO) and assigned to either the immediate intervention or comparator (delayed intervention) arm. Initial allocation was set to 66% and amended to 85% after 61 participants had been randomised to achieve balance [Participants and the trial statistician (BG) were blinded to group allocation. Outcome assessments were digitally self-reported by participants (remotely and independently of a researcher) directly into the P1vital